ARMP News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

AR

Mkt Cap

$125.3M

Volume

134.64K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Pseudomonal Infections Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 10+ Leading Players Wheeling the Therapeutics LandscapeDelveInsight's 2026 report highlights a robust pipeline for pseudomonal infections treatment with 10+ active pharmaceutical companies developing innovative therapies. Key players including Armata Pharmaceuticals, Respirion Pharmaceuticals, and AstraZeneca are advancing promising candidates like AP-PA02, RSP-1502, and AZD0292 through clinical trials. Recent developments include Respirion's successful Phase Ib completion of RSP-1502 and Armata's encouraging Phase II results for AP-PA02, addressing the significant unmet medical need in treating antibiotic-resistant Pseudomonas aeruginosa infections.GlobeNewswire Inc. · Mar 16, 2026

Armata Posts 59 Percent Q2 Revenue JumpArmata Pharmaceuticals reported Q2 2025 results with $2.2 million in GAAP revenue, exceeding estimates. The company achieved positive Phase 1b/2a trial results for its AP-SA02 bacteriophage therapy targeting Staphylococcus aureus bacteremia, while managing ongoing financial challenges.The Motley Fool · Aug 13, 2025

Innoviva (INVA) Q2 Sales Jump 64%Innoviva reported Q2 2025 earnings with $0.77 EPS and $100.3 million revenue, exceeding analyst expectations. Specialty therapeutics sales increased 54% year-over-year, driven by new product launches like GIAPREZA and ZEVTERA, while operating income declined due to increased R&D expenses.The Motley Fool · Aug 7, 2025

8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - Pipeline Innovations Expected to Add $1.8 Billion in Bronchiectasis Market SalesThe report forecasts the bronchiectasis treatment market to reach $3.7 billion by 2033, driven by emerging pipeline agents expected to contribute an additional $1.8 billion in sales.GlobeNewswire Inc. · May 23, 2025

Phage Therapies Clinical Trial Pipeline Shows Potential with Active Contributions from 20+ Key Companies | DelveInsightThe phage therapy market is experiencing significant growth due to the increasing prevalence of antibiotic-resistant infections and the growing interest in alternative treatments. Advances in biotechnology and ongoing research are driving innovation in phage-based therapeutics, offering a promising solution to combat multidrug-resistant pathogens.GlobeNewswire Inc. · Jan 23, 2025

Bronchiectasis Market to Show Positive Growth at a CAGR of 13.7% by 2034 | DelveInsightThe bronchiectasis market is expected to grow at a CAGR of 13.7% from 2024 to 2034, driven by the launch of new treatments like Brensocatib and CMS I-neb, advancements in diagnostics, and the increasing incidence of the disease.GlobeNewswire Inc. · Jan 21, 2025

Groundbreaking Insights Unveiled in Non-Cystic Fibrosis Bronchiectasis Pipeline ReportThe report discusses emerging therapies for non-cystic fibrosis bronchiectasis, a chronic lung condition, including Brensocatib and HSK31858, which are in advanced clinical trials and show promise in reducing inflammation and improving patient outcomes.GlobeNewswire Inc. · Nov 28, 2024

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue EstimatesY-mAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -12.50% and 0.53%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · Nov 13, 2023

Armata Pharma (ARMP) Stock Surges 130% in a Month: Here's WhyArmata Pharma (ARMP) stock skyrockets 130% in a month due to encouraging progress of the company's pathogen-targeting natural and synthetic phage candidates.Zacks Investment Research · Aug 22, 2023

Armata Pharmaceuticals, Inc. (ARMP) Now Trades Above Golden Cross: Time to Buy?When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?Zacks Investment Research · Aug 17, 2023

AR

ARMPArmata Pharmaceuticals, Inc. Common Stock

ARMP

Pay with—

Available Balance0.00

Your PositionYou don't own any ARMP yet.

Related Tickers

Earnings